Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.

AstraZeneca’s Covid-19 vaccine accurately follows the genetic instructions programmed into AZD1222 by the developers to successfully provoke a strong immune response, according to a detailed analysis carried out by independent UK scientists.

Brazilian health authority Anvisa said a volunteer in a clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University died, stating it had received data from an investigation into the matter.

Pfizer Inc. and BioNTech SE announced the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the novel coronavirus.

More than half of Covid-19 patients discharged from hospitals still experienced symptoms of breathlessness, fatigue, anxiety and depression for two to three months after their initial infection, according to the findings of a small UK study.

Johnson & Johnson temporarily paused the company’s Covid-19 vaccine candidate clinical trials due to an unexplained illness in a study participant, delaying one of the highest-profile efforts to contain the global pandemic.

Oxford University will study whether the world’s best-selling prescription medicine adalimumab was an effective treatment for Covid-19 patients in the latest effort to repurpose existing drugs as potential coronavirus therapies.

Britain will host clinical trials where volunteers are deliberately infected with the new coronavirus to test the effectiveness of vaccine candidates, the Financial Times reported, citing people involved in the project.

Europe’s healthcare regulator endorsed using dexamethasone to treat Covid-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.

The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.